APOE and diabetes mellitus: Adding the 22 metabolite‐signature to a reference predictive model (conditioned on age, gender and education, and including ApoE‐ε4, diabetes, BMI and number of medications) increased the predictive performance for cognitive decline from a cross‐validated AUC of 62% (95% CI 56–67%) to 75% (95% CI 70–80%) (Figure 2).